"Ibogaine produces a profound long-lasting psychedelic state, potentially lasting 24-48 hours. Many describe the dream-like experience as a personal 'life review.'"
"In the late 20th century, individuals who took ibogaine reported dramatic decreases in opioid or cocaine cravings, with withdrawal symptoms blunted or absent."
"Trump's new executive order is removing legal impediments from studying psychedelics like ibogaine and prioritizing rescheduling under the 'Right to Try' law."
"Early laboratory and clinical work suggest that ibogaine interacts with multiple receptor systems and may help 'rewire' circuits involved in addiction, depression, and PTSD."
Ibogaine, a psychoactive alkaloid from the Tabernanthe iboga shrub, has been used in spiritual ceremonies in Africa. It induces a long-lasting psychedelic state, often described as a life review. Observations in the late 20th century revealed that ibogaine could significantly reduce cravings for opioids and cocaine, leading to interest in its anti-addiction properties. Despite its potential, ibogaine remains a Schedule I substance in the U.S. Recent executive orders aim to facilitate research and rescheduling, potentially allowing broader access to this treatment for addiction and other conditions.
Read at Psychology Today
Unable to calculate read time
Collection
[
|
...
]